Similar articles

• Moving beyond fluorouracil for colorectal cancer.

  Mayer RJ. Mayer RJ. N Engl J Med. 2000 Sep 28;343(13):963-4. doi: 10.1056/NEJM200009283431309. N Engl J Med. 2000. PMID: 11006373 No abstract available.
• Irinotecan/5-fluorouracil/leucovorin in advanced colorectal cancer: Oncologic Drugs Advisory committee summary.

  Oncologic Drugs Advisory Committee. Oncologic Drugs Advisory Committee. Clin Colorectal Cancer. 2002 May;2(1):8-10. Clin Colorectal Cancer. 2002. PMID: 12453328 No abstract available.
• Postmarketing re-evaluation of irinotecan plus 5-fluorouracil/leucovorin for first-line treatment of metastatic colorectal cancer.

  Chico IM, Pazdur R. Chico IM, et al. Clin Colorectal Cancer. 2002 May;2(1):11-2. doi: 10.1016/S1533-0028(11)70495-9. Clin Colorectal Cancer. 2002. PMID: 12453329 No abstract available.
• [Irinotecan plus fluorouracil and leucovorin for advanced colorectal cancer].

  Motomura S. Motomura S. Nihon Rinsho. 2003 Sep;61 Suppl 7:360-3. Nihon Rinsho. 2003. PMID: 14574913 Review. Japanese. No abstract available.
• Irinotecan and 5-FU/ leucovorin in metastatic colorectal cancer: balancing efficacy, toxicity, and logistics.

  Hwang JJ. Hwang JJ. Oncology (Williston Park). 2004 Dec;18(14 Suppl 14):26-34. Oncology (Williston Park). 2004. PMID: 15685831 Review.